PURETHAL Mites / HAL Allergy - LARVOL DELTA

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM) (clinicaltrials.gov) - P3 | N=552 | Active, not recruiting | Sponsor: HAL Allergy

New P3 trial • Allergic Rhinitis • Allergy • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases

The Effectiveness of Allergen Immunotherapy in Adult Patients with Atopic Dermatitis Allergic to House Dust Mites. (PubMed, Medicina (Kaunas)) - "Additionally, the proportion of patients who achieved success in the IsGA (IsGA < 2) was significantly better in comparison to the placebo with 13/20 (65%) vs. 4/14 (29%), respectively (p < 0.05). HDM-AIT effectively improved atopic dermatitis in patients that strictly qualified for desensitisation with a confirmed monovalent mite allergy."

Journal • Allergy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Biological treatment added to allergen immunotherapy increases its efficacy (EAACI 2022) - "Conclusion AIT to HDM allergens was more effective in reducing asthmatic symptoms when omalizumab was added in patients with HDM-driven asthma. Further studies are necessary."

Clinical • Immunology